153 related articles for article (PubMed ID: 10321012)
21. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
[TBL] [Abstract][Full Text] [Related]
22. Influence of a cyclic combination chemotherapeutic protocol on primary haemostasis in dogs suffering from malignant lymphoma.
Eberle N; Mischke R
Vet J; 2010 Mar; 183(3):298-304. PubMed ID: 19185520
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma.
Rassnick KM; McEntee MC; Erb HN; Burke BP; Balkman CE; Flory AB; Kiselow MA; Autio K; Gieger TL
J Vet Intern Med; 2007; 21(6):1364-73. PubMed ID: 18196748
[TBL] [Abstract][Full Text] [Related]
24. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases.
Sorenmo K; Overley B; Krick E; Ferrara T; LaBlanc A; Shofer F
Vet Comp Oncol; 2010 Sep; 8(3):196-208. PubMed ID: 20691027
[TBL] [Abstract][Full Text] [Related]
25. Treatment of canine lymphoma with COPLA/LVP.
Boyce KL; Kitchell BE
J Am Anim Hosp Assoc; 2000; 36(5):395-403. PubMed ID: 10997514
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
Chun R; Garrett LD; Vail DM
J Vet Intern Med; 2000; 14(2):120-4. PubMed ID: 10772481
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
Siedlecki CT; Kass PH; Jakubiak MJ; Dank G; Lyons J; Kent MS
Can Vet J; 2006 Jan; 47(1):52-9. PubMed ID: 16536229
[TBL] [Abstract][Full Text] [Related]
28. Comparison of combination l-asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi-centric T-cell or hypercalcaemic lymphoma.
Angelo G; Cronin K; Keys D
J Small Anim Pract; 2019 Jul; 60(7):430-437. PubMed ID: 30790291
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs.
Mutsaers AJ; Glickman NW; DeNicola DB; Widmer WR; Bonney PL; Hahn KA; Knapp DW
J Am Vet Med Assoc; 2002 Jun; 220(12):1813-7. PubMed ID: 12092954
[TBL] [Abstract][Full Text] [Related]
30. Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.
Blake MK; Carr BJ; Mauldin GE
Can Vet J; 2016 Feb; 57(2):176-82. PubMed ID: 26834270
[TBL] [Abstract][Full Text] [Related]
31. Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma.
Lautscham EM; Kessler M; Ernst T; Willimzig L; Neiger R
Vet Rec; 2017 Mar; 180(12):303. PubMed ID: 28100766
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.
Keller ET; MacEwen EG; Rosenthal RC; Helfand SC; Fox LE
J Vet Intern Med; 1993; 7(5):289-95. PubMed ID: 8263847
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma.
Intile JL; Rassnick KM; Al-Sarraf R; Chretin JD
J Am Anim Hosp Assoc; 2019; 55(2):101-109. PubMed ID: 30653362
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and adverse events of continuous l-asparaginase administration for canine large cell lymphoma of presumed gastrointestinal origin.
Nakagawa T; Kojima M; Ohno K; Chambers JK; Uchida K; Ohmi A; Goto-Koshino Y; Tomiyasu H; Tsujimoto H
Vet Comp Oncol; 2022 Mar; 20(1):102-108. PubMed ID: 34213084
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
[TBL] [Abstract][Full Text] [Related]
36. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Wang SL; Lee JJ; Liao AT
Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
[TBL] [Abstract][Full Text] [Related]
37. Prednisolone inclusion in a first-line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results.
Zandvliet M; Rutteman GR; Teske E
Vet J; 2013 Sep; 197(3):656-61. PubMed ID: 23746872
[TBL] [Abstract][Full Text] [Related]
38. In vitro immune monitoring of antibody response in dogs given chemoimmunotherapy for lymphoma.
Jeglum KA; Winters WD; Young KM
Am J Vet Res; 1989 Apr; 50(4):488-92. PubMed ID: 2712415
[TBL] [Abstract][Full Text] [Related]
39. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
40. Histologic classification as an indication of therapeutic response in malignant lymphoma of dogs.
Gray KN; Raulston GL; Gleiser CA; Jardine JH
J Am Vet Med Assoc; 1984 Apr; 184(7):814-7. PubMed ID: 6725115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
